Xeris Biopharma Holdings, Inc. (XERS)
Xeris Biopharma (XERS) Reports Break-Even Earnings for Q3
Xeris Biopharma (XERS) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.01. This compares to a loss of $0.06 per share a year ago.
Xeris Biopharma (XERS) Surges 14.2%: Is This an Indication of Further Gains?
Xeris Biopharma (XERS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
What Makes Xeris Biopharma (XERS) a Strong Momentum Stock: Buy Now?
Does Xeris Biopharma (XERS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Xeris Biopharma (XERS) Upgraded to Buy: Here's Why
Xeris Biopharma (XERS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run?
Xeris Biopharma (XERS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Xeris Biopharma Holdings, Inc. (XERS) Q2 2025 Earnings Call Transcript
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Allison Wey - Senior Vice President of Investor Relations & Corporate Communications John P. Shannon - CEO & Director Steven M.
Xeris Biopharma (XERS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Xeris Biopharma (XERS) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates
Xeris Biopharma (XERS) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.1 per share a year ago.
Xeris Biopharma: Great Numbers, Great Technologies, And Suitable For Long-Term Investing
Compared to other biotech companies, Xeris Biopharma Holdings Inc. is a company that has successfully launched products that are already generating revenue. As the company's revenue is expected to grow significantly by 2030, the stock price may rise accordingly. Moreover, XP-8121 may serve as a catalyst for higher stock valuation.
Xeris Biopharma Holdings, Inc. (XERS) Q1 2025 Earnings Call Transcript
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q1 2025 Results Conference Call May 8, 2025 8:30 AM ET Company Participants Allison Wey - SVP of IR, Corporate Communications John Shannon - CEO Steve Pieper - CFO Conference Call Participants David Amsellem - Piper Sandler Eason Lee - Leerink Partners Jason Dorr - Oppenheimer Chase Knickerbocker - Craig-Hallum Operator Good morning. Thank you for attending today's Xeris Biopharma First Quarter 2025 Results Conference Call.
Xeris Biopharma (XERS) Reports Q1 Loss, Tops Revenue Estimates
Xeris Biopharma (XERS) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.14 per share a year ago.
Xeris Biopharma Holdings: Looking For More Growth In Q1 Earnings
Xeris Biopharma Holdings, Inc. has shown consistent double-digit growth and is expected to continue this trend, with Q1 earnings projected to drive the share price higher. Key metrics to watch include Gvoke and Recorlev revenues, EPS, adjusted EBITDA, and cash flow, as these will determine Xeris's path to profitability. Risks include potential underperformance in product revenue, rising SG&A expenses, and any delays in pipeline programs like XP-8121.
